We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 0.03% | 1,584.00 | 1,583.50 | 1,584.00 | 1,585.00 | 1,575.00 | 1,579.50 | 746,246 | 11:52:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.21 | 65.11B |
From Apr 2019 to Apr 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday that the European Commission has approved Strimvelis, the stem-cell gene therapy aimed at treating patients with a rare immunodeficiency disease called ADA-SCID.
The healthcare company said Strimvelis is indicated for the treatment of patients with ADA-SCID for whom no suitable human donor is available.
The marketing-authorization decision was based on data collected from 18 children treated with Strimvelis, the company said.
Shares at 1500 GMT were down 4 pence, or 0.3%, at 1453 pence, valuing the company at 70.78 billion pounds ($104 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
May 27, 2016 11:44 ET (15:44 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
